{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T03:54:12Z","timestamp":1771732452032,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.clinthera.2016.12.001","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T17:04:58Z","timestamp":1483635898000},"page":"178-189.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Indirect Treatment Comparisons of Ibrutinib Versus Physician\u2019s Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"39","author":[{"given":"Sonja","family":"Sorensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Wildgust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishan","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Trambitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzy","family":"van Sanden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.12.001_bib1","unstructured":"Orphan Products: Hope for People With Rare Diseases. Last updated 2016. U.S.Food and Drug Administration Web site. http:\/\/www.fda.gov\/Drugs\/ResourcesForYou\/Consumers\/ucm143563.htm. Accessed September 20, 2016."},{"key":"10.1016\/j.clinthera.2016.12.001_bib2","unstructured":"Medicines for rare diseases. Last updated 2016. European Medicines Agency Web site. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/special_topics\/general\/general_content_000034.jsp. Accessed September 20, 2016."},{"key":"10.1016\/j.clinthera.2016.12.001_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.disamonth.2012.01.009","article-title":"Chronic lymphocytic leukemia","volume":"58","author":"Shanshal","year":"2012","journal-title":"Dis Mon"},{"key":"10.1016\/j.clinthera.2016.12.001_bib4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/ejh.12468","article-title":"Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century","volume":"94","author":"Pulte","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clinthera.2016.12.001_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clinthera.2016.12.001_bib6","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2016.12.001_bib7","unstructured":"National Cancer Institute. SEER Cancer Statistics Review, 1975-2013. Last updated 2013. National Cancer Institute Web site. http:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed July 20, 2016."},{"key":"10.1016\/j.clinthera.2016.12.001_bib8","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2007-12-129379","article-title":"Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2016.12.001_bib9","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.6004\/jnccn.2014.0125","article-title":"Non-Hodgkin\u2019s lymphomas, version 4.2014","volume":"12","author":"Zelenetz","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2016.12.001_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1756-8722-6-59","article-title":"Ibrutinib and novel BTK inhibitors in clinical development","volume":"6","author":"Akinleye","year":"2013","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clinthera.2016.12.001_bib11","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3109\/10428194.2013.777837","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)","volume":"54","author":"Burger","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2016.12.001_bib12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/asheducation-2013.1.553","article-title":"Targeting B-cell receptor signaling: changing the paradigm","volume":"2013","author":"Fowler","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clinthera.2016.12.001_bib13","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood.V124.21.3331.3331","article-title":"Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE\u2122 trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"124","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2016.12.001_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.12.001_bib15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/asheducation-2010.1.481","article-title":"Understanding and managing ultra high-risk chronic lymphocytic leukemia","volume":"2010","author":"Stilgenbauer","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clinthera.2016.12.001_bib16","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2016.12.001_bib17","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2016.12.001_bib18","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/L15-5144-2","article-title":"The PRISMA Extension Statement","volume":"163","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2016.12.001_bib19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0272989X13487604","article-title":"Evidence synthesis for decision making 1: introduction","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clinthera.2016.12.001_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428194.2015.1122783","article-title":"Phase III, randomized study of ofatumumab versus physicians\u2019 choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia","volume":"57","author":"Osterborg","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2016.12.001_bib21","doi-asserted-by":"crossref","first-page":"7023","DOI":"10.1200\/jco.2015.33.15_suppl.7023","article-title":"Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL)","volume":"33","author":"Jones","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2016.12.001_bib22","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood.V124.21.4684.4684","article-title":"Ofatumumab (OFA) vs. physician\u2019s choice (PC) of therapy in patients (pts) with bulky fludarabine refractory (BFR) chronic lymphocytic leukaemia (CLL): results of the phase III study OMB114242","volume":"124","author":"\u00d6sterborg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2016.12.001_bib23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40273-014-0145-y","article-title":"Methods for adjusting for bias due to crossover in oncology trials","volume":"32","author":"Ishak","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2016.12.001_bib24","unstructured":"European Medicines Agency. Summary of opinion. Zydelig. Last updated 2016. European Medicines Agency Web site. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/003843\/WC500202365.pdf. Accessed July 20, 2016."},{"key":"10.1016\/j.clinthera.2016.12.001_bib25","unstructured":"National Institute of Health and Care Excellence. Technology appraisal guidance: Idelalisib for treating of chronic lymphocytic leukaemia. Last updated 2015. NICE Web site. https:\/\/www.nice.org.uk\/guidance\/ta359\/resources\/idelalisib-for-treating-chronic-lymphocytic-leukaemia-82602676706245. Accessed July 20, 2016."},{"key":"10.1016\/j.clinthera.2016.12.001_bib26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2016.12.001_bib27","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood.V126.23.2944.2944","article-title":"Comparing single-agent ibrutinib, bendamustine plus rituximab (BR) and ibrutinib plus BR in patients with previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an indirect comparison of the RESONATE and HELIOS trials","volume":"126","author":"Hillmen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2016.12.001_bib28","doi-asserted-by":"crossref","first-page":"A432","DOI":"10.1016\/j.jval.2015.09.1032","article-title":"Bayesian network meta-analysis to assess relative efficacy of ibrutinib versus idelalisib+ofatumumab and physician\u2019s choice in relapsed\/refractory Cll patients","volume":"18","author":"Diels","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2016.12.001_bib29","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816309146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816309146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T15:20:59Z","timestamp":1601306459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816309146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0149291816309146"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.12.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indirect Treatment Comparisons of Ibrutinib Versus Physician\u2019s Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}